Treatment of disorders of adult bronchial secretion, especially in acute bronchial and acute episodes of chronic bronchopneumopathies


The mean dose of ambroxol hydrochloride is 60 mg to 120 mg daily in 2 divided doses, ie 1 to 2 tablets twice daily.
Ambroxol has mucokinetic and expectorant properties.

It stimulates, by its action on the secretory cells, the secretion, bronchial and promotes the production of a more mobilizable mucus.It increases the ciliary activity.
Not applicable.

History of hypersensitivity reactions to any of the constituents

The association of a mucomodifier with a cough suppressant and / or drying substances and (atropic) secretions is irrational.

This medicinal product contains lactose and is not recommended for use in patients with lactose intolerance

Not applicable.

Not applicable.

Not applicable.


Studies in animals have not shown any teratogenic effect. In the absence of a teratogenic effect in animals, a malformative effect in the human species is not expected.

Indeed, to date, substances responsible for malformations in the human species have been shown to be teratogenic in animals in well-conducted studies of two species
< Br>

In clinical studies, there is currently no adequate data to evaluate a possible malformative or fetotoxic effect of the hydrochloride of ambroxol when administered during pregnancy. >

Therefore, as a precautionary measure, it is preferable not to use ambroxol hydrochloride during pregnancy.

In case of breast-feeding, the use of this product is not recommended.
Possible gastrointestinal disorders Minors such as nausea, vomiting, gastralgia, rapidly yielding to decreased dosage

ยท Have been described

O Cases of mucocutaneous reactions to type, erythema, rash, pruritus, urticaria

O very rarely anaphylactoid manifestations with an outbreak of shock and edema of Quincke that have been favorable in the cases reported

In these cases the treatment must be interrupted.

Cases of headache and vertigo have also been described very rarely.